JAK inhibitor shows promise in psoriasis as Incyte presents positive Phase II data
This article was originally published in Scrip
Executive Summary
Incyte's INCB39110, a JAK1 inhibitor, has shown efficacy in chronic plaque psoriasis, with results from a Phase II study presented 3 October. Incyte's results not only add to the stream of potential products lining up to disrupt the psoriasis landscape, they also highlight the potential of the JAK inhibitor class outside of cancer indications.